Antagonists targeting downstream effectors of the SHH pathway, specifically smoothened (SMO) and GLI1, have been developed as cancer therapeutics and are FDA-approved in the treatment of basal cell carcinomas37, tumors driven by the activation of the SHH pathway. The gene discussed is GLI1; the disease is cancer.